Suven Life Sciences Limited (SUVEN) - Total Liabilities
Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has total liabilities worth Rs561.36 Million INR (≈ $6.07 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Suven Life Sciences Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Suven Life Sciences Limited to evaluate short-term liquidity relative to the company's equity base.
Suven Life Sciences Limited Competitors by Total Liabilities
The table below lists competitors of Suven Life Sciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sgis Songshan Co Ltd
SHE:000717
|
China | CN¥12.19 Billion |
|
Tianma Bearing Group Co Ltd
SHE:002122
|
China | CN¥1.37 Billion |
|
Global Top E Commerce Co Ltd
SHE:002640
|
China | CN¥2.45 Billion |
|
Hangzhou Gaoxin Rubber & Plastic Materials Co Ltd
SHE:300478
|
China | CN¥300.68 Million |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
USA | $601.89 Million |
|
SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
NASDAQ:HDL
|
USA | $354.24 Million |
|
UBISOFT ENTMT ADR 1/5
F:UEN0
|
Germany | €2.75 Billion |
|
Sirio Pharma
SHE:300791
|
China | CN¥3.07 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Suven Life Sciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Suven Life Sciences Limited (SUVEN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Suven Life Sciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Suven Life Sciences Limited (2005–2025)
The table below shows the annual total liabilities of Suven Life Sciences Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs251.97 Million ≈ $2.72 Million |
+69.54% |
| 2024-03-31 | Rs148.62 Million ≈ $1.61 Million |
+9.35% |
| 2023-03-31 | Rs135.91 Million ≈ $1.47 Million |
+14.32% |
| 2022-03-31 | Rs118.89 Million ≈ $1.29 Million |
-41.75% |
| 2021-03-31 | Rs204.12 Million ≈ $2.21 Million |
-47.10% |
| 2020-03-31 | Rs385.84 Million ≈ $4.17 Million |
-81.44% |
| 2019-03-31 | Rs2.08 Billion ≈ $22.48 Million |
+42.28% |
| 2018-03-31 | Rs1.46 Billion ≈ $15.80 Million |
-1.74% |
| 2017-03-31 | Rs1.49 Billion ≈ $16.08 Million |
-21.80% |
| 2016-03-31 | Rs1.90 Billion ≈ $20.57 Million |
-11.06% |
| 2015-03-31 | Rs2.14 Billion ≈ $23.12 Million |
-3.76% |
| 2014-03-31 | Rs2.22 Billion ≈ $24.03 Million |
+23.66% |
| 2013-03-31 | Rs1.80 Billion ≈ $19.43 Million |
+14.10% |
| 2012-03-31 | Rs1.57 Billion ≈ $17.03 Million |
+62.51% |
| 2011-03-31 | Rs968.96 Million ≈ $10.48 Million |
+11.77% |
| 2010-03-31 | Rs866.89 Million ≈ $9.38 Million |
+20.90% |
| 2009-03-31 | Rs717.02 Million ≈ $7.75 Million |
-22.18% |
| 2008-03-31 | Rs921.44 Million ≈ $9.96 Million |
+28.47% |
| 2007-03-31 | Rs717.22 Million ≈ $7.76 Million |
+35.80% |
| 2006-03-31 | Rs528.14 Million ≈ $5.71 Million |
-3.25% |
| 2005-03-31 | Rs545.88 Million ≈ $5.90 Million |
-- |
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more